BioSpace News Archive

The Chartis Group, a leading provider of comprehensive advisory services and analytics to the healthcare industry, is pleased to announce the appointment of Dr. Roger Ray as its Chief Physician Executive.

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Dr. Stephen Hoge, President, will participate in the Chardan Virtual 4th Annual Genetic Medicines Conference on October 5, 2020 at 2:00 p.m. ET.

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced the introduction of two new products designed to enhance patient care in endoscopy and surgical imaging by improving procedural workflow: the OEP-6 high-definition printer and the WM-NP3 workstation.

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced changes in its executive leadership and Board of Directors. João Siffert, M.D. resigned from his positions as CEO, Head of Research and Development, and Chief Medical Officer, as well as member of the Board of Directors, on September 23, 2020

Animalcare to Invest $5 million , Consisting of $ 3 million to Acquire One-Third Stake in STEM Animal Health, Kane Biotech’s New Animal Health Subsidiary , and $2 million for R ight s to C ommercialize P roducts in Global V eterinary M arkets Outside of the Americas Animalcare to Launch Biofilm Oral Care Range for Companion Animals in European and Asian Markets WINNIPEG, Manitoba, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Kane Biotech I

AscellaHealth, a national specialty pharmacy benefit manager (SPBMTM) serving commercial, Medicare and Medicaid segments, was ranked 6th on the Philadelphia Business Journal’s 2019 “Soaring 76” list of fastest-growing companies in greater Philadelphia region as measured by revenue over a three-year period from 2017 through 2019.

Accent Therapeutics today announced that it has been named by Fierce Biotech as one of 2020’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. Accent is a leader in the development of small molecule therapies that selectively inhibit RNA-modifying proteins (RMPs) that drive cancer. By targeting RMPs, the company is taking a novel appr

FibroGenesis, the leading developer of fibroblast based therapeutic solutions for unmet medical needs, is pleased to announce it has entered into a manufacturing agreement with iBiologics to supply its proprietary allogeneic fibroblast ce

Aligos Therapeutics, Inc. (Aligos), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the Company has received approval for a clinical trial application (CTA) for a first-in-human Phase 1a/b proof-of-concept clinical trial. Aligos may now commence study ALG-000184-201 (NCT04536337) to evaluate ALG-000184, a small mole

Demonstrates predictive capability of chemical kinetics in assessing clinical-stage molecules for Alzheimer’s disease (“AD”) Significant paper published in Nature Structural and Molecular Biology Co-authored by Wren’s scientific founders and senior Biogen scientists Aducanumab compared, in a blinded study, to three clinical-stage antibodies using chemical kinetics Only aducanumab dramatically reduces the flux of amyloid-β ol